91 related articles for article (PubMed ID: 22208045)
41. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Mahller YY; Rangwala F; Ratner N; Cripe TP
Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
[TBL] [Abstract][Full Text] [Related]
42. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
43. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
44. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
45. Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway.
Eisenberg DP; Carpenter SG; Adusumilli PS; Chan MK; Hendershott KJ; Yu Z; Fong Y
Surgery; 2010 Aug; 148(2):325-34. PubMed ID: 20633729
[TBL] [Abstract][Full Text] [Related]
46. Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.
Mi YX; Long YH; Li YC
World J Gastroenterol; 2008 Mar; 14(9):1321-5. PubMed ID: 18322942
[TBL] [Abstract][Full Text] [Related]
47. Immunity in latent Herpes simplex virus infection.
Bystrická M; Russ G
Acta Virol; 2005; 49(3):159-67. PubMed ID: 16178513
[TBL] [Abstract][Full Text] [Related]
48. Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1.
Wood LW; Shillitoe EJ
Cancer Gene Ther; 2011 Oct; 18(10):685-94. PubMed ID: 21701533
[TBL] [Abstract][Full Text] [Related]
49. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
50. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
51. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
52. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
Mace AT; Ganly I; Soutar DS; Brown SM
Head Neck; 2008 Aug; 30(8):1045-51. PubMed ID: 18615711
[TBL] [Abstract][Full Text] [Related]
53. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.
Veerapong J; Bickenbach KA; Shao MY; Smith KD; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2007 Sep; 67(17):8301-6. PubMed ID: 17804745
[TBL] [Abstract][Full Text] [Related]
54. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
55. The Herpes Simplex Virus Neurovirulence Factor γ34.5: Revealing Virus-Host Interactions.
Wilcox DR; Longnecker R
PLoS Pathog; 2016 Mar; 12(3):e1005449. PubMed ID: 26964062
[No Abstract] [Full Text] [Related]
56. Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix.
Kolodkin-Gal D; Zamir G; Edden Y; Pikarsky E; Pikarsky A; Haim H; Haviv YS; Panet A
J Virol; 2008 Jan; 82(2):999-1010. PubMed ID: 17977977
[TBL] [Abstract][Full Text] [Related]
57. Virotherapy: The next addition to the standard of care for glioblastoma?
Broekman MLD; Nieland L; Hoeben RC
Cancer Cell; 2022 Oct; 40(10):1089-1091. PubMed ID: 36179688
[TBL] [Abstract][Full Text] [Related]
58. [Oncolytic virus therapy using recombinant HSV-1 for prostate cancer].
Kakutani S; Fukuhara H; Homma Y
Nihon Rinsho; 2016 May; 74 Suppl 3():244-7. PubMed ID: 27344736
[No Abstract] [Full Text] [Related]
59. Oncolytic Herpes Simplex Virus Glioblastoma Therapy is Potentiated by Tumor Necrosis Factor-α Inhibition.
Pointer KB; Zhang RR; Kuo JS
Neurosurgery; 2015 Aug; 77(2):N18-20. PubMed ID: 26181790
[No Abstract] [Full Text] [Related]
60. [Oncolytic virus therapy using herpes simplex virus 1(HSV-1)].
Fukuhara H; Homma Y
Nihon Rinsho; 2011 Jun; 69 Suppl 5():564-7. PubMed ID: 22208045
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
